edoc

β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant

Dörr, Marcus and Schmidt, Carsten O. and Spielhagen, Thomas and Bornhorst, Alexa and Hentschel, Katharina and Franz, Christina and Empen, Klaus and Kocher, Thomas and Diehl, Scott R. and Kroemer, Heyo K. and Völzke, Henry and Ewert, Ralf and Felix, Stephan B. and Rosskopf, Dieter. (2010) β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant. Pharmacogenomics, 11 (9). pp. 1209-1221.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/44014/

Downloads: Statistics Overview

Abstract

Impaired heart rate (HR) response to exercise is associated with increased cardiovascular morbidity and mortality. We analyzed whether common variants (rs5443/C825T and rs5442/G814A) in the G-protein β3 subunit (GNB3) gene modulate interindividual variation in β-blocker responses with respect to HR.; Among 1614 subjects (347 current β-blocker users) of a population-based study, HR during symptom-limited exercise testing was analyzed by multilevel linear regression models adjusted for potential confounders.; In β-blocker users, but not in nonusers, HR was attenuated in rs5443 T allele carriers (TC/TT vs CC) with lower adjusted HR over the entire exercise period from rest to peak workload (3.5 bpm; 95% CI: 1.1-5.8; p < 0.01), and during recovery (4.2 bpm; 95% CI: 0.6-7.8; p = 0.02). The genotype-related HR reducing effect at peak exercise varied by up to 7.5 bpm (CC vs TT), more than a third (35.9%) of the total β-blocker effect (20.9 bpm). By contrast, rs5442 had no impact on any HR-related parameter.; In this population-based sample, a common GNB3 polymorphism (C825T) was significantly related with response to β-blocker therapy with respect to HR during exercise and HR recovery, respectively. Further prospective studies are needed to confirm these associations and to examine their potential clinical relevance.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Biopharmazie (Meyer zu Schwabedissen)
UniBasel Contributors:Prestin, Katharina
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Future Medicine
ISSN:1462-2416
e-ISSN:1744-8042
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:29 Nov 2017 10:07
Deposited On:29 Nov 2017 10:07

Repository Staff Only: item control page